US › Healthcare

Citius Oncology, Inc. (CTOR)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$0.77+2.95%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Net profit

$-8.9M

EPS

$-0.08

EPS estimate

$-0.07

Net margin

-597.4%

EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.

Key statistics

Market cap

$83.8M

Forward P/E

10.1

P/B

2.65

Book value

$0.38

EPS (TTM)

$-0.48

52-week high

$2.25

52-week low

$0.49

50-day MA

$0.86

200-day MA

$0.87

Beta

3.40

Analyst view

Analysts rate Citius Oncology, Inc. a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders

77.51%

Institutions

15.21%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	8.23%
Bank of America Corp	3.63%
Vanguard Capital Management, LLC	0.52%
UBS Group AG	0.32%
Geode Capital Management, LLC	0.23%
Vanguard Fiduciary Trust Co	0.12%
IFP Advisors, LLC	0.10%
Citadel Advisors Llc	0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Citius Oncology, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.